TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 52,500 shares of the biopharmaceutical company's stock after buying an additional 10,500 shares during the quarter. Hussman Strategic Advisors Inc.'s holdings in TG Therapeutics were worth $2,070,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Segall Bryant & Hamill LLC increased its stake in shares of TG Therapeutics by 7.5% in the 1st quarter. Segall Bryant & Hamill LLC now owns 85,471 shares of the biopharmaceutical company's stock valued at $3,370,000 after purchasing an additional 5,953 shares in the last quarter. Victory Capital Management Inc. increased its stake in TG Therapeutics by 70.4% during the 1st quarter. Victory Capital Management Inc. now owns 92,081 shares of the biopharmaceutical company's stock worth $3,631,000 after buying an additional 38,047 shares in the last quarter. Sigma Planning Corp purchased a new stake in TG Therapeutics during the 1st quarter worth approximately $1,252,000. Edgestream Partners L.P. increased its stake in TG Therapeutics by 21.4% during the 1st quarter. Edgestream Partners L.P. now owns 65,249 shares of the biopharmaceutical company's stock worth $2,573,000 after buying an additional 11,511 shares in the last quarter. Finally, CWM LLC increased its stake in TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after buying an additional 290 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is owned by company insiders.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded down $0.46 on Friday, hitting $38.73. 187,085 shares of the company were exchanged, compared to its average volume of 2,454,468. The stock has a market capitalization of $6.15 billion, a price-to-earnings ratio of 160.94 and a beta of 1.91. The company has a 50-day moving average price of $36.33 and a 200 day moving average price of $35.46. TG Therapeutics, Inc. has a 1-year low of $16.65 and a 1-year high of $46.48. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company's revenue was up 90.4% on a year-over-year basis. As a group, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a research note on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.